3PL Pharmaceutical Licensing Requirements: Federal, State & Cold Chain Compliance Guide (2026)

Third-party logistics providers handling pharmaceutical products operate under a distinct regulatory framework from wholesale drug distributors. Licensing requirements vary by state, and a national 3PL may need 30-50 separate licenses to operate legally. This guide covers federal DSCSA requirements, state-by-state licensing, cold chain compliance, and how to verify 3PL authorization status.

What Is a Pharmaceutical Third-Party Logistics Provider

A pharmaceutical third-party logistics provider (3PL) provides warehousing, storage, inventory management, and distribution services for manufacturers and wholesale distributors without taking ownership of pharmaceutical products. The 3PL operates under contractual arrangements, handling physical possession and movement of drugs on behalf of the product owner.

Under Section 581(22) of the Drug Supply Chain Security Act (DSCSA), a 3PL is defined as an entity that "provides or coordinates warehousing, or other logistics services of a product in interstate commerce on behalf of a manufacturer, wholesale distributor, or dispenser of a product, but does not take ownership of the product, nor have responsibility to direct the sale or disposition of the product."

This includes:

• Warehouse storage and climate control
• Inventory management and lot tracking
• Order fulfillment and kitting
• Transportation coordination
• Returns processing and reverse logistics

A 3PL's revenue comes from service fees—charges for storage space, handling, and logistics coordination.

How 3PLs Differ from Wholesale Drug Distributors

Wholesale drug distributors purchase pharmaceutical products, take legal ownership, and resell them to downstream trading partners. The distributor buys at one price and sells at a markup. This ownership transfer is the core of the business model. For a comprehensive overview of wholesale distributor operations and licensing, see the Wholesale Pharmaceutical Distributors guide.

3PLs never own the product. They hold possession temporarily while providing logistics services. When a 3PL ships product to a pharmacy, the transaction occurs between the manufacturer (or wholesale distributor) and the pharmacy. The 3PL facilitates movement but is not party to the sale.

This ownership distinction determines which entity generates DSCSA transaction documentation. Under DSCSA Section 582, wholesale distributors must provide Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS) when transferring ownership. 3PLs are exempt from this requirement because no ownership change occurs when they handle product. For details on these transaction documentation requirements, see the DSCSA compliance checklist for wholesale distributors.

Why the Ownership Distinction Matters for Licensing

The ownership distinction triggers entirely different regulatory frameworks. Wholesale distributors are licensed under Section 503(e) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Third-party logistics providers are licensed under DSCSA Section 584—a separate legal authority enacted specifically to regulate 3PLs as distinct entities.

DSCSA Section 584 explicitly states: "No State shall regulate third-party logistics providers as wholesale distributors." This preemption clause prevents states from applying wholesale distributor licensing requirements to 3PLs, recognizing that the business models and compliance risks differ fundamentally.

However, 3PLs are still subject to state licensing. Section 584 requires each 3PL facility to be licensed by the state from which the drug is distributed. If a state has not established a compliant 3PL licensing program, the FDA itself licenses those facilities.

DSCSA Transaction Documentation Requirements

Because 3PLs never take ownership, they do not generate:

• Transaction Information (TI): Product identifier, transaction date, shipment information
• Transaction History (TH): Chain of ownership from manufacturer through each transaction
• Transaction Statement (TS): Attestation that the transaction complies with DSCSA

The manufacturer or wholesale distributor that owns the product remains responsible for providing these documents to the receiving trading partner. The 3PL's role is physical logistics, not documentation of ownership transfer.

3PLs must still maintain records of products received and distributed, including lot numbers, expiration dates, and transaction details. But the legal obligation to produce TI/TH/TS falls on the product owner, not the logistics provider.

Trading Partner Verification

While 3PLs do not generate transaction documents, they are defined as "trading partners" under DSCSA. This classification carries verification obligations. Each trading partner in the pharmaceutical supply chain must verify that entities they conduct transactions with are authorized.

For a 3PL, this means verifying that the manufacturers and wholesale distributors whose products they handle are properly registered and licensed. For manufacturers and distributors engaging a 3PL, this means verifying the 3PL holds the required state licenses and has reported to FDA. For step-by-step verification procedures, see How to verify a wholesale drug distributor's license.

Federal Requirements Under DSCSA Section 584

Section 584 establishes two core federal obligations for all pharmaceutical 3PLs: state or federal licensure for each facility, and annual reporting to FDA.

Per-Facility Licensing Requirement

Each 3PL facility must be licensed by the state from which the drug is distributed. If the state has not established a licensing program that complies with Section 584, the 3PL must obtain licensure directly from FDA.

"Facility" means a physical location where drugs are stored or from which they are distributed. A 3PL operating warehouses in Pennsylvania, Texas, and California needs three separate licenses—one from each state (or from FDA if a state lacks a program).

This differs from some state wholesale distributor licensing schemes that issue a single license covering multiple facilities under common ownership. DSCSA Section 584 requires individual facility licensure.

Annual FDA Reporting via CDER Direct

Section 584(b) requires each 3PL to report the following information to FDA annually:

• Name, address, and contact information for each facility
• State licensure information for each facility
• Trade names under which the 3PL conducts business
• Type of services provided
• Disciplinary actions taken against the 3PL by any state or federal agency

Reporting is conducted through FDA's CDER Direct system. The deadline is January 31 each year, covering the previous calendar year's information.

FDA maintains a publicly accessible database of 3PLs that have reported. This database allows manufacturers, wholesale distributors, and dispensers to verify that a 3PL holds authorized trading partner status.

Consequences of Non-Reporting

Failure to submit the annual report results in loss of "authorized trading partner" status. Under DSCSA, trading partners may only conduct transactions with authorized entities. A 3PL that has not reported to FDA cannot legally handle DSCSA-regulated products.

If a manufacturer or distributor engages a non-reporting 3PL, both entities may be subject to enforcement action. The manufacturer/distributor violated the requirement to verify trading partner status. The 3PL operated without proper authorization.

Which Entities Qualify as 3PLs

The DSCSA definition of 3PL includes entities that "provide or coordinate warehousing, or other logistics services." This encompasses:

• Traditional warehouse operators: Facilities that receive, store, and ship pharmaceutical products on behalf of clients
• Returns processors: Entities that accept returned products, verify lot numbers and expiration dates, and coordinate disposition with the product owner
• Reverse logistics providers: Facilities handling product recalls, expired inventory removal, and returns from pharmacies or wholesalers

The definition explicitly excludes:

• Common carriers: Transportation providers (UPS, FedEx, specialized pharma couriers) that move product but do not operate storage facilities
• Brokers: Entities that arrange transactions between parties but never take physical possession
• IT service providers: Software platforms that facilitate supply chain coordination but do not handle physical product
• Entities without physical facilities: Virtual coordinators that arrange services but operate no warehouses

To qualify as a 3PL under Section 584, the entity must accept or transfer direct possession of products and operate a physical facility where drugs are stored.

The State-by-State Licensing Patchwork

Before DSCSA's enactment in 2013, most states had no separate regulatory category for third-party logistics providers. Pharmaceutical warehousing was either unregulated or lumped into wholesale distributor licensing schemes. Entities providing logistics services without taking ownership were often forced to obtain wholesale distributor licenses despite the business model mismatch.

DSCSA Section 584 required states to establish separate 3PL licensing programs or cede authority to FDA. States have responded unevenly. As of 2026, some have created dedicated 3PL license categories with tailored requirements. Others continue to apply wholesale distributor frameworks. Some have no program at all, defaulting to federal licensure.

States with Dedicated 3PL License Categories

Florida issues a Third Party Logistics Provider License through the Division of Drugs, Devices, and Cosmetics. The application requires facility information, description of services, and proof of compliance with storage and handling standards. Florida conducts facility inspections and requires annual renewal. For complete details on Florida's requirements, see the Florida wholesale drug distributor license guide.

Iowa created a 3PL Provider License under Iowa Code Chapter 155A. The initial application fee is $750 per location, with annual renewal at the same rate. If the 3PL handles controlled substances, a separate Controlled Substance Act registration is required ($90 biennial fee). Iowa requires facility managers to have minimum experience and conducts pre-licensure inspections.

Ohio allows out-of-state 3PLs to meet requirements through home-state licensure or NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation. This reciprocity approach reduces the application burden for multi-state operators but still requires verification of compliance with Ohio's standards.

Texas maintains one of the largest pharmaceutical distribution markets in the United States. While Texas primarily regulates wholesale distributors, 3PLs operating facilities in Texas must comply with state board of pharmacy requirements. For details on Texas's regulatory framework, see the Texas wholesale drug distributor license guide.

Several other states have enacted parallel programs with varying application requirements, fee structures, and renewal intervals. The issuing agency differs by state: most assign authority to the state board of pharmacy, but some use the department of health or department of agriculture.

States Without Dedicated 3PL Programs

Michigan requires 3PLs to obtain wholesale drug distributor licenses. The application process, fees, and facility standards are identical to those applied to entities that purchase and resell drugs. This creates compliance friction—3PLs must meet requirements designed for ownership-based distribution models.

South Dakota licenses only in-state 3PLs. Out-of-state 3PLs with no physical facilities in South Dakota are not directly regulated by the state. If a 3PL operates a facility in South Dakota, state licensure is required. If the 3PL operates from another state, South Dakota defers to that state's licensing authority.

States including Hawaii, Idaho, Maine, Maryland, and Massachusetts historically lacked dedicated 3PL licensing categories. Some have since developed programs; others have not. Where no state program exists, 3PLs must file with FDA for federal licensure under Section 584.

Typical Application Requirements

State 3PL license applications generally require:

• Business entity information: legal name, DBA names, ownership structure, parent company relationships
• Officers and owners list: names, titles, addresses for all individuals with ownership interest or operational control
• Description of services provided: warehousing, distribution, returns processing, cold chain capabilities
• Facility manager information: name, qualifications, experience, and responsibilities
• Home state license copy: for non-resident 3PLs applying as out-of-state entities
• NABP accreditation documentation: where applicable as alternative or supplementary requirement
• Customer contracts: examples demonstrating the 3PL's role and service scope
• Customer list: manufacturers and distributors whose products the 3PL handles
• List of states where the 3PL operates: all locations where drugs are stored or distributed
• Proof of general liability insurance: coverage amounts vary by state
• Application fee: ranges from several hundred to several thousand dollars per state

Most states require a facility inspection before issuing the license. Inspectors verify compliance with storage standards, temperature control systems, security measures, and record-keeping practices. The inspection may occur before or shortly after initial licensure, depending on state procedures.

Approval Timeline and Renewal

Application processing time ranges from 4 weeks to 3 months, depending on the state's backlog and inspection scheduling. States with mandatory pre-licensure inspections tend toward the longer end of this range.

Renewal intervals are typically annual, though some states operate on a biennial cycle. The renewal application requires updated facility information, confirmation that no material changes have occurred, and payment of the renewal fee (often equal to the initial application fee).

3PLs must report address changes, contact information updates, and ownership changes within 10 to 20 days (varies by state). Licenses are facility-specific and owner-specific—they are not transferable. A change in ownership triggers the need for a new license application, even if the facility and operations remain unchanged.

Cold Chain and Temperature-Controlled Storage Requirements

3PLs handling temperature-sensitive pharmaceuticals operate under a distinct compliance framework beyond basic state licensing. Biologics, vaccines, gene therapies, and many specialty pharmaceuticals require continuous temperature control from manufacturing through delivery. Failure to maintain specified temperature ranges can degrade product efficacy, trigger costly recalls, and expose patients to ineffective or unsafe drugs.

Temperature Zones and Storage Infrastructure

Pharmaceutical products are classified into four temperature categories, each requiring dedicated storage infrastructure:

• Controlled room temperature (CRT): 20-25°C (68-77°F). Standard pharmaceutical storage for most oral solids and non-refrigerated products.
• Refrigerated: 2-8°C (36-46°F). Required for insulin, most vaccines, many biologics, and temperature-sensitive compounded preparations.
• Frozen: -25 to -10°C (-13 to 14°F). Cell therapies, certain vaccines, and products requiring long-term stability at sub-zero temperatures.
• Ultra-low: -70°C (-94°F) and below. mRNA vaccines, viral vectors for gene therapy, and research-grade biologics.

A 3PL serving specialty pharmaceutical clients must operate multiple temperature zones simultaneously within the same facility. This requires:

• Segregated storage areas: Physical separation prevents cross-contamination and inadvertent temperature exposure. Walk-in coolers, freezers, and ultra-low chambers must be clearly marked and access-controlled.
• Redundant refrigeration systems: Backup compressors, generators, and automatic failover to prevent loss during equipment failure or power outages.
• Real-time monitoring: IoT sensors at pallet, zone, and facility levels transmitting continuous temperature data. Industry standard: readings every 1-5 minutes.
• Automated excursion alerts: Temperature deviations trigger instant mobile alerts to facility managers and quality teams. Response protocols require investigation and corrective action within 15 minutes.
• Warehouse management system (WMS) integration: Automated assignment of products to temperature-appropriate zones, first-expired-first-out (FEFO) rotation, and lot tracking tied to temperature history.

Regulatory Standards for Cold Chain Operations

Cold chain compliance is governed by multiple overlapping standards:

FDA Current Good Manufacturing Practice (cGMP) regulations under 21 CFR Part 211 establish temperature control requirements for storage and distribution. While cGMP technically applies to manufacturers, FDA guidance extends these principles to 3PLs as part of the extended supply chain.

USP <1079> Good Storage and Distribution Practices for Drug Products provides non-binding recommendations for maintaining product integrity during storage and transportation. Many 3PL contracts and quality agreements incorporate USP <1079> as a contractual compliance standard.

WHO Good Distribution Practices (GDP) guidelines serve as the international reference standard. The World Health Organization's Technical Report Series includes detailed recommendations for temperature monitoring, validation, and documentation.

EU GDP (2013/C 343/01) is considered the global gold standard for pharmaceutical distribution. Even U.S.-based 3PLs serving European markets or global pharmaceutical companies often adopt EU GDP requirements to demonstrate best-in-class cold chain capability.

3PLs serving Canadian markets must comply with Health Canada GUI-0069, which establishes Good Manufacturing Practices for pharmaceutical distributors and includes temperature control requirements.

Cost and Risk of Cold Chain Operations

Cold storage costs 25-40% more than ambient warehousing. The premium reflects:

• Energy costs: $0.15-$0.30 per square foot per month for refrigeration and climate control systems
• Equipment maintenance: 15-20% of equipment capital value annually for preventive maintenance, calibration, and repairs
• Compliance infrastructure: $50,000-$100,000+ annually for monitoring systems, validation studies, and regulatory documentation
• Labor premium: Cold storage workers earn 20-30% more than ambient warehouse staff due to specialized skills and working conditions

Temperature excursions carry severe financial consequences. A single excursion event—temperature deviation outside specified range for a duration exceeding product stability limits—results in average losses of $100,000 to $500,000. Affected product lots must be quarantined, investigated, and often destroyed. Industry estimates place annual global biopharma losses from temperature excursions at $35 billion.

The financial risk extends beyond direct product loss. Excursions trigger:

• Regulatory reporting obligations to FDA and state boards of pharmacy
• Customer notification and potential contract termination
• Increased inspection frequency and regulatory scrutiny
• Reputational damage affecting new business development

Cold Chain for Clinical Trial Logistics

Clinical trial supply chains impose additional cold chain complexity. Cell and gene therapies may require up to four layers of specialized packaging:

1. Cryobag or vial containing the product
2. Liquid nitrogen dry shipper maintaining ultra-low temperature
3. Outer insulated container with dry ice or phase-change materials
4. Protective overpack for transportation compliance

3PLs supporting clinical trials must plan excursion allowances and delivery windows three years in advance during protocol development. Investigational products lack the stability data of commercial drugs, requiring conservative temperature specifications and tighter monitoring.

Multi-site, multi-country clinical trial distribution adds regulatory complexity. Each jurisdiction may have different requirements for investigational product handling, import/export documentation, and temperature validation.

Multi-State Compliance Challenges

A 3PL operating a national distribution network faces a compliance matrix that dwarfs the challenges of single-state operators. Each state maintains its own application process, renewal schedule, inspection protocols, and reporting obligations. A 3PL with facilities in 15 states may need 30-50 licenses when accounting for resident and non-resident requirements.

The Licensing Coordination Problem

State licensing programs operate independently. Application requirements differ. Fee structures vary. Some states process applications in 30 days; others take 90 days or longer. Inspection scheduling depends on state staffing and priorities, creating unpredictable timelines.

The coordination challenge intensifies when manufacturer and 3PL licensing requirements intersect. Some states require the 3PL to hold an active license before the manufacturer using that 3PL can obtain its own state license. If the 3PL's application is delayed, the manufacturer's application is blocked.

Manufacturer-3PL Licensing Misalignment Risks

When manufacturer and 3PL licensing status diverges, distribution may be deemed unauthorized:

Scenario 1: Manufacturer licensed, 3PL not licensed. Carriers may hold shipments at state borders pending verification of the 3PL's authorization. Delivery delays trigger cold chain excursions, expiring delivery windows, and customer complaints. State boards of pharmacy may issue enforcement actions against both the unlicensed 3PL and the manufacturer that engaged an unauthorized service provider.

Scenario 2: 3PL licensed, manufacturer not licensed. The 3PL possesses valid authorization to handle drugs, but the products being handled are not authorized for distribution in that state. Distribution is unauthorized. Both entities face penalties.

Scenario 3: Both licensed, but renewal lapse. A 3PL operating in 40 states must track 40 renewal deadlines. Missing a single renewal creates an authorization gap. If the manufacturer is unaware and continues using the facility, both parties operate in violation until the license is reinstated.

Some state enforcement actions impose penalties on both the unlicensed entity and any party that engaged them. This joint-and-several liability model means manufacturers cannot rely solely on 3PL assurances—they must independently verify licensing status.

Virtual Manufacturer Licensing Requirements

Virtual manufacturers—entities that own products but outsource all manufacturing and distribution to third parties—face particularly complex licensing requirements. Research compiled by state licensing consultants indicates:

• Virtual manufacturers must hold their own state licenses in at least 34 states
• Only 17 states allow virtual manufacturers to rely solely on the 3PL's license
• Virtual manufacturers self-distributing (selling directly to pharmacies or clinics) need licenses in at least 47 states

This creates a scenario where the manufacturer, the contract manufacturer, and the 3PL may each need separate licenses in overlapping jurisdictions. Determining which entity needs which licenses requires jurisdiction-by-jurisdiction analysis.

Best Practices for Multi-State Compliance

Manufacturers and 3PLs can reduce licensing misalignment risk through:

Joint licensing matrix: Create a shared spreadsheet tracking both parties' licensing status in all relevant states, including application dates, approval dates, renewal deadlines, and inspection schedules. Update monthly.

Contractual licensing obligations: Quality agreements and logistics service agreements should specify which party is responsible for obtaining and maintaining licenses in each jurisdiction. Include notification requirements if either party's license is suspended, revoked, or allowed to lapse.

Regulatory change monitoring: Subscribe to state board of pharmacy updates and rulemaking notices in all operating states. States frequently update requirements without comprehensive advance notice to affected entities.

Professional licensing services: Multi-state operators increasingly use specialized licensing firms to manage applications, track renewals, and monitor regulatory changes across all 50 states. The cost of outsourcing is typically lower than the internal staff time and missed-deadline risk of self-management.

NABP Drug Distributor Accreditation for 3PLs

The National Association of Boards of Pharmacy (NABP) operates the Drug Distributor Accreditation program, formerly known as Verified-Accredited Wholesale Distributors (VAWD). While the program was originally designed for wholesale distributors, NABP updated criteria in December 2025 to explicitly address third-party logistics providers. For comprehensive details on the accreditation process, see the NABP VAWD accreditation guide.

Eligibility and Source Verification Requirements

A 3PL seeking NABP accreditation may only distribute products on behalf of:

1. FDA-registered manufacturers: The 3PL must verify current FDA establishment registration for each manufacturer whose products it handles.
2. NABP-accredited wholesale distributors: Distributors that have completed the Drug Distributor Accreditation process and hold active accreditation status.
3. Non-accredited wholesale distributors that meet two conditions: (a) purchase products directly from FDA-registered manufacturers, and (b) hold valid licenses in all states where the 3PL distributes those products.

The 3PL must implement and document verification processes for each source. Verification includes checking FDA registration status, state licensure in relevant jurisdictions, and NABP accreditation status (where claimed). NABP requires re-verification at least annually.

This requirement creates a cascading compliance chain. If a 3PL handles products from 50 different manufacturers and distributors, it must verify and maintain current documentation for all 50 entities. If any source's license lapses or accreditation expires, the 3PL must cease handling that source's products until authorization is restored.

Virtual Manufacturer and Virtual Distributor Requirements

NABP criteria impose specific obligations on virtual entities seeking accreditation:

Virtual manufacturers (entities that sell products manufactured under contract) must utilize an NABP-accredited 3PL for distribution. Virtual manufacturers must also "sell or transfer ownership from a licensed location"—meaning the entity must hold a license in the jurisdiction from which products are distributed, even if the physical distribution is performed by the 3PL.

Virtual wholesale distributors (entities that purchase products but outsource storage and distribution) must utilize an NABP-accredited 3PL and must purchase directly from FDA-registered manufacturers or from accredited distributors. Virtual distributors cannot rely on non-accredited intermediaries.

These requirements effectively make NABP accreditation a prerequisite for any 3PL seeking to serve virtual pharmaceutical companies.

Co-Location and Separation Requirements

3PLs co-located with other businesses—such as a pharmaceutical 3PL operating within a broader logistics facility handling consumer goods—must demonstrate physical separation and clear audit trails. NABP requires:

• Distinct storage areas with controlled access
• Separate inventory management systems or clearly delineated records
• Personnel training specific to pharmaceutical handling
• Quality systems that prevent commingling with non-pharmaceutical products

Co-location is permissible, but the pharmaceutical operation must be identifiable and separable for audit and inspection purposes.

Accreditation Cost and Timeline

NABP increased Drug Distributor Accreditation fees in December 2024. Total cost for a three-year accreditation cycle is approximately $12,500, broken down as:

• Application and Supplemental Compliance Inspection (SCI) phase
• Drug Distributor Accreditation (DDA) assessment phase
• Three-year accreditation maintenance

The SCI phase increased by $900; the DDA phase increased by $1,220 from previous pricing.

The accreditation process includes document submission, facility inspection by NABP-approved inspectors, and remediation of any deficiencies identified during inspection. Timeline from application to accreditation typically spans 4-6 months, depending on inspection scheduling and any required corrective actions.

December 2025 Criteria Changes

The December 2025 update removed the liability insurance requirement that previously required accredited entities to maintain minimum insurance coverage. NABP also replaced generic "transaction history" requirements with explicit references to DSCSA Section 582 provisions, aligning accreditation criteria more closely with federal statutory obligations.

These changes reduce the administrative burden on 3PLs while maintaining the core verification and quality system requirements that form the basis of accreditation.

How ColdChainCheck Tracks 3PL Compliance

ColdChainCheck maintains a directory of 1,275 pharmaceutical wholesale distributors, 3PLs, and cold chain logistics providers. Each entity receives a compliance score (0-100) based on verified data across six dimensions: state licensing, NABP accreditation, FDA registration, regulatory enforcement actions, business history, and data completeness.

The average compliance score across all tracked entities is 51 out of 100, placing most entities in the "Fair" tier. Only 28 entities (2.2%) achieve scores of 80 or above ("Excellent" tier). 281 entities (22%) score between 60-79 ("Good" tier). The majority—919 entities (72%)—score between 40-59 ("Fair" tier).

State Licensing Coverage

ColdChainCheck tracks 35,146 state licenses across all 51 jurisdictions (50 states plus District of Columbia). Of these, 25,665 licenses (73%) are active. The remaining licenses are expired, suspended, or pending renewal.

For 3PLs operating in multiple states, this cross-referencing capability provides a single view of licensing status across all jurisdictions. A procurement manager can verify whether a 3PL holds active licenses in the specific states where distribution will occur, without manually checking each state board of pharmacy website.

State licensing data is sourced directly from state boards of pharmacy and regulatory agencies. ColdChainCheck updates licensing information as states publish changes, though update frequency varies by jurisdiction based on data availability.

NABP Accreditation Gap

Only 63 entities in the directory hold NABP Drug Distributor Accreditation. This represents 4.9% of tracked entities. The gap is particularly relevant for manufacturers and distributors seeking to engage accredited 3PLs—the pool of options is significantly smaller than the total population of licensed entities.

ColdChainCheck entity profiles indicate NABP accreditation status and, where applicable, accreditation type (wholesale distributor vs. 3PL-specific accreditation). This allows procurement teams to filter for accredited entities when contractual or internal quality requirements mandate NABP verification.

NABP accreditation data is sourced from NABP's public registry and updated as accreditations are issued, renewed, or allowed to lapse.

FDA Registration and Enforcement Actions

1,234 entities (96.8%) in the directory have verified FDA registration. FDA requires 3PLs to report annually via CDER Direct, and ColdChainCheck cross-references entities against FDA's public database of registered facilities.

73 entities (5.7%) have at least one FDA recall, warning letter, or enforcement action on record. These regulatory events are surfaced in entity profiles to provide visibility into compliance history. A recall does not automatically indicate poor current compliance—recalls occur for various reasons, including manufacturing defects discovered after distribution—but the presence of multiple enforcement actions may warrant additional due diligence.

Enforcement data is sourced from FDA's public databases, including the Recall Enterprise System and Warning Letter repository.

Using ColdChainCheck for 3PL Verification

Entity profiles consolidate all tracked compliance data in a single view:

• Active state licenses by jurisdiction
• NABP accreditation status and type
• FDA registration status
• Regulatory enforcement history
• Business entity information (headquarters location, corporate structure)

Users can search the directory by entity name, state, or compliance score tier. For procurement teams building approved vendor lists or conducting trading partner verification, the directory provides a starting point for due diligence—though it does not replace the need for direct verification with the entity and relevant regulatory authorities.

Search the ColdChainCheck directory →

The compliance score methodology is transparent and disclosed on each entity profile, showing the breakdown across all six scoring dimensions. This allows users to understand why an entity received a particular score and assess whether the scoring criteria align with their internal vendor qualification requirements.

For additional guidance on DSCSA compliance obligations, see the DSCSA small dispenser compliance 2026 guide.

Disclaimer: ColdChainCheck provides regulatory data aggregation and compliance scoring for informational purposes only. The data is based on publicly available information and is updated periodically. Users should independently verify all licensing and compliance information with the relevant entity and regulatory authorities before making procurement or partnership decisions. ColdChainCheck scores do not constitute regulatory approval, legal advice, or recommendations. Compliance verification is the responsibility of each trading partner.